Neoadjuvant Pembrolizumab Improves Event-Free Survival in Advanced Melanoma Patients
核心洞察
A phase II clinical trial demonstrates that patients with high-risk stage III or IV melanoma (搜索) receiving pembrolizumab before and after surgery achieved 72% event-free survival at two years compared to 49% with post-surgery treatment alone.
The study represents the first randomized trial to confirm that timing of surgery matters in melanoma (搜索) treatment, with neoadjuvant-adjuvant pembrolizumab significantly improving outcomes without added toxicity.
Researchers suggest this approach could change clinical practice for sequencing immunotherapy and surgery, though questions remain about optimal treatment duration and potential surgical de-escalation.
Patients with high-risk, advanced-stage melanoma (搜索) who received pembrolizumab both before and after surgery demonstrated significantly longer event-free survival compared to those receiving immunotherapy only after surgery, according to a phase II clinical trial published in the New England Journal of Medicine.
The randomized trial involved patients with high-risk stage III or stage IV melanoma (搜索) who were assigned to either receive neoadjuvant pembrolizumab for nine weeks followed by surgery and then adjuvant pembrolizumab for a total of one year, or undergo surgery followed by adjuvant pembrolizumab only for one year or until disease recurrence or adverse events occurred.
Clinical Trial Results
After a 15-month follow-up period, the combined neoadjuvant-adjuvant group demonstrated significantly longer event-free survival than the adjuvant-only group. Event-free survival at two years reached 72% in the neoadjuvant-adjuvant group compared to just 49% in the adjuvant-only group.
"This showed us for the first time in a randomized trial design that timing of surgery really does matter," said Sunandana Chandra, MD, MS, associate professor of Medicine in the Division of Hematology and Oncology at Northwestern University and co-author of the study.
The primary endpoint was event-free survival, with adverse events including disease progression, toxic effects that prevented surgical resection or initiation of adjuvant therapy, surgical complications, melanoma (搜索) recurrence after surgery, and death from any cause.
Treatment Protocol and Safety
The study findings suggest that neoadjuvant-adjuvant pembrolizumab can significantly improve event-free survival for patients with advanced melanoma (搜索) without added toxic effects. The treatment protocol involved administering pembrolizumab for nine weeks before surgery, followed by surgical resection, and then continuing pembrolizumab treatment for the remainder of the one-year period.
Clinical Implications
The results could influence how clinicians approach the sequencing of therapy and surgery in melanoma (搜索) treatment. However, several questions remain for future investigation, according to Chandra.
"Now that we have this intriguing data showing that the sequencing of immunotherapy and surgery does matter, some questions we have are: do we even need the post-surgery adjuvant therapy, and for how long? Would we potentially in the future be able to deescalate surgery to minimize surgical morbidity? Will this approach lead to an overall survival benefit?" Chandra said.
The research was conducted by investigators including Jeffrey Sosman, MD, professor of Medicine in the Division of Hematology and Oncology, who served as co-author of the study. Both Chandra and Sosman are members of the Robert H. Lurie Comprehensive Cancer Center (搜索) of Northwestern University.
The work was supported by grants from the National Cancer Institute of the National Institutes of Health and in part by Merck Sharp and Dohme (搜索), a subsidiary of Merck.